Patients with rheumatoid arthritis and diabetes saw greater improvement in blood glucose levels with sarilumab than adalimumab or placebo, shows
a study spresented at Clinical Congress of Rheumatology West 2019.
A clinical trial recently presented at Clinical Congress of Rheumatology West 2019, shows that tofacitinib improved the quality of life for patients with psoriatic arthritis who did not have adequate response to DMARDs or TNF inhibitors.
The oral therapy filgotinib could be a more effective treatment for patients with active ankylosing spondylitis who also do not adequately respond to nonsteroidal anti-inflammatory drugs (NSAIDs), according to the results of a phase two trial.
Even though gout is a known co-morbidity among kidney transplant patients, occurring in approximately 25 percent of patients at some point, little is known about the number of transplant patients who will develop the condition or how long it might take to appear.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: MultiMedia Healthcare
535 Connecticut Avenue, Suite 300
Norwalk, CT, 06854, USA
